Medications such as semaglutide are now widely used to treat type 2 diabetes and obesity, so even uncommon potential side effects can become important when millions of people are exposed to a treatment. One area receiving closer attention is eye health, particularly after a systematic review and meta-analysis published in Neurology found an association between semaglutide use and nonarteritic anterior ischemic optic neuropathy, or NAION, a rare condition that can cause sudden, painless vision loss.
The finding deserves attention, but it also needs perspective. The reported increase was substantial when expressed as relative risk, while the condition itself remained uncommon. Just as importantly, the evidence came largely from observational studies, which can identify an association but cannot establish that semaglutide directly caused the optic nerve injury.
What Is NAION?
NAION occurs when blood supply to part of the optic nerve becomes insufficient, resulting in damage to the nerve. Vision loss is typically sudden and painless and commonly affects one eye, and some degree of permanent visual impairment can remain.
Several established NAION risk factors overlap with the health conditions for which semaglutide is often prescribed. These include type 2 diabetes, high blood pressure, obstructive sleep apnea, and other vascular factors, while certain optic nerve anatomy may also increase susceptibility. That overlap makes the relationship difficult to untangle because a patient taking semaglutide may already have underlying conditions that raise the likelihood of optic nerve vascular problems independent of the medication.
Earlier observational studies had also produced conflicting results, which is one reason researchers undertook the new meta-analysis.
What Did the Meta-Analysis Find?
Researchers reviewed studies published through April 5, 2025, looking at NAION among people using GLP-1 receptor agonists compared with patients receiving other treatments. Five studies formed the primary analysis, representing 1,593,554 patients. Of those, 682,456 were semaglutide users and 911,098 were receiving non-GLP-1 receptor agonist treatments.
Semaglutide use was associated with a relative risk of 2.52 compared with non-GLP-1 receptor agonists. Expressed as a percentage, that is an estimated 152% increase in relative risk, but that figure needs to be considered alongside the absolute number of cases.
Across more than 1.1 million semaglutide users included in the incidence analysis, the researchers estimated 118 NAION cases per 100,000 users. Across the GLP-1 receptor agonist group more broadly, the pooled estimate was 85 cases per 100,000 users. Those estimates came from studies with different populations and follow-up periods, so they should not be interpreted as a simple annual risk for every person taking semaglutide.
Relative Risk and Absolute Risk Tell Different Stories
This study is a useful example of why both measures matter. A relative risk of 2.52 means NAION occurred more often among semaglutide users than among the comparison groups included in the analysis, but it does not mean that NAION is common among people taking the drug.
The event remained rare in the large populations studied. For clinicians and patients, both pieces of information belong in the conversation: the research identified a meaningful statistical association, while the absolute number of cases remained low.
That distinction is particularly important with rare adverse events, where a large percentage increase can sound much more alarming than the underlying frequency suggests.
The Association Remained Strong in People With Diabetes
The researchers also examined patients with diabetes separately. In that group, semaglutide use was associated with a relative risk of 2.41 compared with non-GLP-1 receptor agonist treatments.
Interpreting that result is complicated because diabetes itself is an established vascular risk factor for NAION. People prescribed semaglutide may also differ from patients taking other treatments in disease severity, cardiovascular risk, blood pressure, weight, sleep apnea, and other characteristics that are difficult to fully control in observational research.
The authors therefore rated the certainty of the overall evidence as low to moderate. Their conclusion was not that semaglutide had been proven to cause NAION, but that the signal warranted further investigation and should be considered in clinical risk-benefit discussions.
Why Might Semaglutide and NAION Be Connected?
At this point, there is no established biological explanation. Researchers and clinicians have discussed several possibilities, including changes in blood pressure and vascular regulation that might affect blood flow to an already vulnerable optic nerve.
Changes associated with substantial weight loss could also alter blood pressure and other cardiovascular factors over time, particularly in patients already taking medications that influence blood pressure. These remain hypotheses, and the available evidence cannot determine whether the association reflects a direct effect of semaglutide, an indirect effect associated with treatment, or differences in the health profiles of people who receive the medication.
That uncertainty matters because a biologically plausible explanation is not the same as a demonstrated mechanism.
The Benefits of Semaglutide Still Belong in the Conversation
Any discussion of a rare potential adverse effect also has to account for why semaglutide is prescribed in the first place. GLP-1 receptor agonists can provide substantial benefits for appropriate patients with type 2 diabetes and obesity, including improvements in glycemic control, weight management, and cardiovascular outcomes.
The Neurology researchers did not conclude that patients should discontinue semaglutide because of the NAION findings. Instead, the evidence supports including the possible association in clinical risk-benefit discussions while further research clarifies the relationship.
A rare potential ocular risk therefore needs to be considered alongside the established systemic benefits of treatment and the individual health profile of the patient.
What Should Eye Care Professionals Take From the Research?
For eye care professionals, the expanding use of GLP-1 receptor agonists makes medication history increasingly relevant when assessing sudden optic nerve or visual changes. Knowing which medications a patient uses, when treatment began, and which vascular or metabolic risk factors are present can provide useful context during an examination.
Sudden, painless vision loss requires prompt ophthalmic evaluation regardless of whether a patient is taking semaglutide. The study also reinforces the importance of avoiding simple conclusions from an emerging safety signal because NAION has multiple established risk factors, while the people most likely to receive semaglutide often already have several of them.
What We Know So Far
The meta-analysis strengthens the evidence that an association may exist between semaglutide use and NAION, but it does not establish that the medication directly causes the condition. NAION remained uncommon in the populations studied, and the researchers described the overall certainty of the evidence as low to moderate.
For now, the most useful response is awareness rather than alarm. As semaglutide and other GLP-1 receptor agonists become more widely used, better prospective research will be needed to identify which patients, if any, face increased ocular risk and whether the association reflects the drug itself, the effects of treatment, or the underlying health conditions shared by many of its users.
Sources
Petrova K. Weight-loss drugs linked to rare eye condition in massive data review. PsyPost. Published August 22, 2026. Read the original article.
Dhivagaran T, Butt F, Arunasalam L, et al. Glucagon-like Peptide-1 Receptor Agonists and Risk of Nonarteritic Anterior Ischemic Optic Neuropathy: Systematic Review and Meta-Analysis. Neurology. 2026.
